Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 14;19(3):565-576.
doi: 10.5114/aoms/159113. eCollection 2023.

Efficacy and safety of sacubitril/valsartan in heart failure compared to renin-angiotensin-aldosterone system inhibitors: a systematic review and meta-analysis of randomised controlled trials

Adrian V Hernandez  1   2 , Vinay Pasupuleti  3 , Nancy Scarpelli  1 , Jack Malespini  1 , Maciej Banach  4   5 , Agata M Bielecka-Dabrowa  4   5
Affiliations
Review

Efficacy and safety of sacubitril/valsartan in heart failure compared to renin-angiotensin-aldosterone system inhibitors: a systematic review and meta-analysis of randomised controlled trials

Adrian V Hernandez et al. Arch Med Sci. .

Abstract

Introduction: Heart failure (HF) is still a major cause of morbidity and mortality all over the world. Aim of the study was to assess the benefits and harms of sacubitril/valsartan (S/V) compared to angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) in patients with HF.

Material and methods: We systematically searched for randomised controlled trials (RCTs) evaluating S/V vs. ACEI or ARB in acute or chronic HF in August 2021. Primary outcomes were HF hospitalisations and cardiovascular (CV) mortality; secondary outcomes included all-cause mortality, biomarkers, and renal function.

Results: We selected 11 RCTs (n = 18766) with 2-48 months follow-up. Five RCTs had ACEIs as control, 5 RCTs had ARBs as control, and one RCT had both ACEI and ARB as control. Compared to ACEI or ARB, S/V reduced HF hospitalisations by 20% (HR = 0.80, 95% CI: 0.68-0.94; 3 RCTs; I2 = 65%; high CoE), CV mortality by 14% (HR = 0.86, 95% CI: 0.73-1.01; 2 RCTs; I2 = 57%; high CoE), and all-cause mortality by 11% (HR = 0.89, 95% CI: 0.78-1.00; 3 RCTs; I2 = 36%; high CoE). S/V reduced NTproBNP (SMD = -0.34, 95% CI: -0.52 to -0.16; 3 RCTs; I2 = 62%) and hs-TNT (ratio of differences = 0.84, 95% CI: 0.79-0.88; 2 RCTs; I2 = 0%), and caused a decline in renal function by 33% (HR = 0.67, 95% CI: 0.39-1.14; 2 RCTs; I2 = 78%; high CoE). S/V increased hypotension (RR = 1.69, 95% CI: 1.33-2.15; 9 RCTs; I2 = 65%; high CoE). Hyperkalaemia and angioedema events were similar. Effects were in the same direction when stratified by type of control (ACEI vs. ARB).

Conclusions: Sacubitril/valsartan had better clinical, intermediate, and renal outcomes in HF in comparison to ACEI or ARB. There was no difference in angioedema and hyperkalaemia events, but there were more hypotension events.

Keywords: LCZ696; heart failure; meta-analysis; renin-angiotensin-aldosterone system inhibitors; sacubitril/valsartan.

PubMed Disclaimer

Conflict of interest statement

M.B. has received research grants/support from Amgen, Mylan/Viatris, Sanofi, and Valeant, and he has served as a consultant/received speakers fee from Amgen, Daiichi-Sankyo, Esperion, Freia Pharmaceuticals, Herbapol, Kogen, KRKA, Mylan/Viatris, Novartis, Novo-Nordisk, Polfarmex, Polpharma, Sanofi-Aventis, Servier, Teva, and Zentiva. He is CMO at the Nomi Biotech Corporation Ltd. A.M.B.-D. has given lectures that were sponsored by Novartis Polska Sp.z o. o. The remaining authors do not have any competing interests to disclose.

Figures

Figure 1
Figure 1
PRISMA flow diagram
Figure 2
Figure 2
Effect of sacubitril/valsartan vs. ACEI or ARB on HF hospitalization
Figure 3
Figure 3
Effect of sacubitril/valsartan vs. ACEI or ARB on CV mortality
Figure 4
Figure 4
Effect of sacubitril/valsartan vs. ACEI or ARB on all-cause mortality
See this image and copyright information in PMC

References

    1. McDonagh T, Metra M, Adamo M, et al. . 2021. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42: 3599-26. - PubMed
    1. Heidenreich PA, Bozkurt B, Aguilar D, et al. . 2022. AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022; 145: e895-e1032. - PubMed
    1. Guha K, McDonagh T. Heart failure epidemiology: European perspective. Curr Cardiol Rev 2013; 9: 123-7. - PMC - PubMed
    1. Van Nuys KE, Xie Z, Tysinger B, et al. . Innovation in heart failure treatment: life expectancy, disability, and health disparities. JACC Heart Failure 2018; 6: 401-9. - PMC - PubMed
    1. Farré N, Vela E, Clèries M, et al. . Real world heart failure epidemiology and outcome: a population-based analysis of 88,195 patients. PLoS One 2017; 12: e0172745. - PMC - PubMed